 |
 |
 |
 |
 |
 |
 |
 |
E-Mail
ShareNRTIs in Development
- Apricitabine Development Should Not Be Halted, Say HIV/AIDS Advocates in Open Letter (June 21, 2010)
From AIDS Treatment Activists Coalition - Avexa Closes Apricitabine Program (May 10, 2010)
Announces CEO resignation, headcount reduction and plan to explore strategic alternatives.
From Avexa Limited - Not Your Everyday Antiretroviral: KP-1461, an HIV DNA Killer (October 11, 2007)
In AIDS Treatment News, from AIDS Treatment News - Development of DFC, an Investigational NRTI, Is Discontinued (April 4, 2006)
From The Body - NRTIs in Development (March 30, 2006)
An overview from Edwin DeJesus, M.D.
From The Body - D-D4FC (RVT, Reverset) Is Active Against NRTI-Resistant Virus in Phase 2B Trial (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - Nucleoside Reverse Transcriptase Inhibitors (June 1, 2002)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - DPC 817: Novel Nucleoside Analog Active Against Drug-Resistant Strains (May 31, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
The Body PRO is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body PRO and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body PRO's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.